Pamlico has developed a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections.
Main aim of the deal is to develop a production cell line from the protein’s amino acid sequence for GMP manufacture of phase I clinical material.
Pamlico Biopharma CEO Clayton Duncan said, "With this agreement, Pamlico Biopharma has reached a milestone in the development of a therapeutic antibody product for the treatment of Streptoccocus pneumoniae, a leading cause of Severe Community Acquired Pneumonia (SCAP) which can lead to hospitalization and death."
Cytovance Biologics president and chief executive officer Darren Head said the company’s facilities and experienced staff are prepared to deliver the highest quality of development and manufacturing services for Pamlico Biopharma.
"We are delighted to be working with such an innovative company that uses technologies from the Oklahoma Medical Research Foundation and advance the treatment of Streptococcus pneumoniae infections that are associated with over 50,000 deaths annually," Head said.
Cytovance specializes in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation.
Apart from its cGMP manufacturing services, the company provides process development, cGMP cell banking and support services from its Oklahoma City facilities.